GlassScriptPhysician profile
Jeffrey L Vacirca
NPI 1366446726
$135,288.49
in general payments reported to CMS, 2019-2025
33 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $41K · 2020: $490 · 2021: $1,333 · 2022: $975 · 2023: $92K · 2024: $170.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $90K · Food and Beverage: $1,948.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $90,000.00 |
| Food and Beverage | $1,948.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Spectrum Pharmaceuticals INC. | $130,150.28 | 2019-2023 | Rolvedon |
| Ipsen Biopharmaceuticals, INC | $1,026.88 | 2021-2022 | |
| Genentech USA, INC. | $455.00 | 2020 | |
| Daiichi Sankyo INC. | $408.94 | 2022-2023 | |
| Siemens Medical Solutions USA, INC. | $348.63 | 2022-2023 | |
| Asd Specialty Healthcare, LLC | $333.86 | 2019-2021 | |
| Genzyme Corporation | $190.40 | 2023 | |
| Karyopharm Therapeutics INC. | $178.65 | 2023 | Xpovio |
| G1 Therapeutics, INC. | $175.20 | 2023 | Cosela |
| Puma Biotechnology, INC. | $163.28 | 2022-2024 | |
| Novartis Pharmaceuticals Corporation | $156.52 | 2022 | |
| Varian Medical Systems, INC. | $147.60 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $145.99 | 2023 | |
| Amneal Pharmaceuticals LLC | $143.82 | 2023-2024 | |
| Servier Pharmaceuticals LLC | $139.11 | 2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $125.00 | 2023 | Lumakras |
| Relievant Medsystems, INC. | $124.99 | 2021 | |
| Glaxosmithkline, LLC. | $116.55 | 2021 | |
| Genentech, INC. | $113.67 | 2019 | |
| Sirtex Medical INC | $100.00 | 2023 | Sir-Spheres Microspheres |
| E.R. Squibb & Sons, L.L.C. | $94.12 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $86.76 | 2019-2022 | |
| Kite Pharma, INC. | $85.46 | 2020-2021 | |
| Epizyme, INC. | $56.92 | 2022 | |
| Genmab U.S., INC. | $55.64 | 2023 | Epkinly |
| Gilead Sciences, INC. | $50.00 | 2022 | |
| Janssen Biotech, INC. | $46.37 | 2021 | |
| Taiho Oncology, INC. | $36.12 | 2022 | |
| Verastem, INC. | $32.73 | 2019 |
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$720,159.85 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Vacirca listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.